Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 832 results for "novartis ag"

Latin America OTC Pharmaceuticals Market 2014-2018 with Bayer ...

Research and Markets (http://www.researchandmarkets.com/research/3ggp7m/otc) has announced the addition of the "OTC Pharmaceuticals Market in Latin America 2014-2018" report to their offering. The OTC Pharmaceuticals Market in Latin America market ... Individual.com, 1 day ago
[x]  

75 images for novartis ag

BusinessWeek, 2 days ago
PBS, 1 day ago
4 Traders, 3 weeks ago
pr-inside.com, 5 days ago
Common Dreams, 4 weeks ago
The Japan News, 1 week ago
Fort Worth Business Press, 1 week ago
Asiaone, 3 weeks ago
Newsday, 1 month ago
Live Trading News, 1 month ago

Proteus Digital Health Grows Leadership Team and Board of Directors with Former Executives from Novartis, Microsoft and Egreetings Network

Proteus Digital HealthTM, a leading digital medicines company, today announced the expansion of the company's executive team and board of directors with the addition of three industry leaders across consumer technology and global pharmaceuticals. ...
 Reuters1 day ago
[x]  
Business Times Singapore

Drug's patent woes cost US patients dearly

[LONDON] A gap in US patent law has kept cheap copies of Novartis AG's heart drug Diovan off the market for 18 months, costing US consumers and insurers as much as US$900 million in potential savings. While the Diovan patent expired in September ...
 Business Times Singapore1 day ago Ranbaxy's Woes Add $900 Million to U.S. Heart Drug Costs  Yahoo! Finance2 days ago Heart Drug Costs $900 Million More as Generic Held Back: Health  GARP1 day ago Ranbaxy, Samsung, Zillow, Scotch: Intellectual Property  Bloomberg1 day ago
[x]  
BusinessWeek

Novartis AG, Weighing $1.3 Billion Offer For ThromboGenics NV

Novartis AG (NOVN) and Shire Plc (SHP) are among drugmakers weighing offers for Belgian eye-medicine company ThromboGenics NV (THR), people familiar with the matter said. Novartis, which is based in Basel, Switzerland, is considered the most likely ...
 BioSpace1 day ago Novartis to Shire Said to Consider Bidding for ThromboGenics  La Repubblica2 days ago Novartis to Shire Said to Weigh Bids for Drugmaker ThromboGenics  Washington Post3 days ago Novartis, Shire Among Interested Buyers for ThromboGenics  Pharmaceutical Manufacturing Magazine2 days ago
[x]  
EuroInvestor

Novartis and Malaria No More provide two million antimalarial treatments to children in Zambia

The FINANCIAL -- Novartis announced that two million treatments of its pediatric antimalarial are arriving in Zambia thanks to the ongoing efforts of the company in collaboration with Malaria No More's Power of One campaign. Zambia is the first ...
 Finchannel.com5 days ago Novartis receives breakthrough therapy designation for meningitis B vaccine  Individual.com1 week ago Novartis data on 19 compounds at AACR highlight strong cancer pipeline across multiple molecular targets and biological pathways  Asian Hospital & Healthcare Management1 week ago Novartis appoints Jeff George as Division Head, Alcon as Kevin Buehler retires; Richard Francis named as new Division Head, Sandoz  Nasdaq1 week ago
[x]  
Boston Globe

Swiss drug maker Novartis cutting RNA interference research group in Cambridge

Swiss drug maker Novartis AG said Monday it is cutting back on a research program in Cambridge trying to develop drugs using a gene-silencing technology called RNA interference. The company has 26 researchers working on RNA medicines and will ...
 Boston Globe2 days ago Novartis AG Thinks Twice About RNAi Development, Slims Down R&D Group In Boston  BioSpace1 day ago Novartis AG To Lay Off 215 NJ Support Staff Employees  BioSpace1 day ago Novartis Q4 net profit rises to $2.0 billion  Economic Times2 months ago

Generic-Drug Makers Oppose Teva Bid to Delay Copaxone Rivals

Generic-drug makers including Momenta Pharmaceuticals Inc. In a court filing today, Momenta, Novartis AG's Sandoz and Mylan Inc. said they would suffer "immense harm" if barred from selling generic Copaxone in the U.S. after some of the drug's ...
 BusinessWeek2 days ago Teva's Generic Copaxone Rivals Asked to Respond on Delay  Bloomberg1 week ago

Novartis Wins Court Order Blocking U.K. Animal-Rights Protests

Novartis AG (NOVN) won a court order restricting animal-rights demonstrations at its U.K. facilities or against any of its employees after lawyers for the drugmaker said they feared it may be targeted. A unit of the drugmaker, which already has an ...
 BusinessWeek2 days ago

Novartis AG (NVS) Showing Bullish Technicals With Support At $81.54

The patented option-trade picking algorithms that power MarketIntelligenceCenter.com's Artificial Intelligence Center Aare highlighting two trades on Novartis AG (http://www.marketintelligencecenter.com/symbol/NVS"NVS) today after it closed at ...
 Individual.com1 week ago Novartis AG (NVS) Showing Support Near $82.70  Individual.com1 week ago Novartis AG (NVS) Showing Resistance Near $84.26  Individual.com1 week ago

Potential Novartis AG (NVS) Trade Has 3.45% Downside Protection

News Story Apr 14, 2014 Potential Novartis AG (NVS) Trade Has 3.45% Downside Protection Apr 14, 2014 (Marketintelligencecenter.com via COMTEX News Network) -- Novartis AG ( NVS ) was selected by MarketIntelligenceCenter.comaEUR(TM)s ...
 PredictWallStreet2 days ago Potential Novartis AG (NVS) Trade Targets 2.50% Return  Individual.com1 day ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - novartis ag
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less